Jan 14, 2014

Lessons from the Diovan scandal

Fallout from the Diovan case in Japan suggests that clinical drug studies on patients should be financed either with public research funds or through formal funding contracts between pharmaceutical companies and the research institutions involved — rather than by pharma donations.